The Prevalence of Diabetes and Thyroid Related Autoantibodies in Sri Lankan Children with Type 1 Diabetes and Their Unaffected Siblings - The Utility of a New Screening Assay

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Feb 23

PMID 36814577

Authors

Navoda Atapattu

Marie Amoroso

Michael Powell

D G Harendra de Silva

K Shamya H de Silva

Jadwiga Furmaniak

Bernard Rees Smith

Lakdasa D Premawardhana

Affiliations

Soon will be listed here.

Abstract

Background: There is limited information about diabetes and thyroid related autoantibodies in children with type 1 diabetes (T1D) or their siblings in Sri Lanka.

Objectives: To assess in T1D children and their unaffected siblings the prevalence of autoantibodies to (1) glutamic acid decarboxylase (GADA), insulinoma associated antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A) using 3 Screen ICA™ (3-Screen) and individual ELISA assays; (2) insulin (IAA); and (3) thyroid peroxidase (TPOA), thyroglobulin (TgA) and the TSH receptor (TSHRA).

Methods: We selected - (a) consecutive T1D children, and (b) their unaffected siblings of both sexes, from the T1D Registry at Lady Ridgeway Hospital, Colombo.

Results: The median age (IQR) of 235 T1D children and 252 unaffected siblings was 11 (8.4, 13.2) and 9 (5.4, 14.9) years respectively, and the duration of T1D was 23 (7, 54) months. (1) T1D children (a) 79.1% were 3-Screen positive; (b) all 3-Screen positives were individual antibody positive (GADA in 74%; IA-2A 31.1%; ZnT8A 38.7%); (c) and were younger (p=0.01 vs 3-Screen negatives); (d) multiple autoantibodies were present in 45.1%; (e) IA-2A (p=0.002) and ZnT8A (p=0.006) prevalence decreased with T1D duration. (f) TPOA and TgA prevalence was higher in T1D children compared to unaffected siblings (28%, p=0.001 and 31%, p=0.004, respectively). (2) Unaffected siblings (a) 6.3% were 3-Screen positive (p=0.001 vs T1D), and 2.4% were positive for IAA; (b) four subjects had two diabetes related autoantibodies, one of whom developed dysglycaemia during follow-up.

Conclusions: The 3-Screen assay, used for the first time in Sri Lankan T1D children and their siblings as a screening tool, shows a high prevalence of T1D related Abs with a high correlation with individual assays, and is also a helpful tool in screening unaffected siblings for future T1D risk. The higher prevalence of thyroid autoantibodies in T1D children is consistent with polyglandular autoimmunity.

Citing Articles

Potential contribution of gut microbiota in the development of autoantibodies in T1D children carrying HLA-DRB1/DQB1 risk alleles: an experimental and in silico analysis.

Shirizadeh A, Razavi Z, Saeedi V, Behzad M, Faradmal J, Solgi G Immunogenetics. 2024; 76(5-6):335-349.

PMID: 39276210 DOI: 10.1007/s00251-024-01354-8.

Estimation of Individual Positive Anti-Islet Autoantibodies from 3 Screen ICA Titer.

Kawasaki E, Jinnouchi H, Maeda Y, Okada A, Kawai K Int J Mol Sci. 2024; 25(14).

PMID: 39062856 PMC: 11277171. DOI: 10.3390/ijms25147618.

Enzyme-linked immunosorbent assay of 3 Screen Islet Cell Autoantibody in patients with autoimmune thyroid disease.

Kawasaki E, Tamai H, Fukuyama T, Sagara Y, Hidaka R, Uchida A World J Diabetes. 2024; 15(5):935-944.

PMID: 38766435 PMC: 11099373. DOI: 10.4239/wjd.v15.i5.935.

South Asian Endocrinology: Challenges and Concerns, Collaboration and Consolidation.

Bhattacharya S, Kalra S Indian J Endocrinol Metab. 2023; 27(5):373-376.

PMID: 38107736 PMC: 10723606. DOI: 10.4103/ijem.ijem_334_23.

References

Atkinson M, Eisenbarth G, Michels A . Type 1 diabetes. Lancet. 2013; 383(9911):69-82. PMC: 4380133. DOI: 10.1016/S0140-6736(13)60591-7. View

Hattersley A . Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med. 1998; 15(1):15-24. DOI: 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M. View

Ilonen J, Lempainen J, Veijola R . The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol. 2019; 15(11):635-650. DOI: 10.1038/s41574-019-0254-y. View

Redondo M, Eisenbarth G . Genetic control of autoimmunity in Type I diabetes and associated disorders. Diabetologia. 2002; 45(5):605-22. DOI: 10.1007/s00125-002-0781-1. View

Ross C, Ward Z, Gomber A, Owais M, Yeh J, Reddy C . The Prevalence of Islet Autoantibodies in Children and Adolescents With Type 1 Diabetes Mellitus: A Global Scoping Review. Front Endocrinol (Lausanne). 2022; 13:815703. PMC: 8851309. DOI: 10.3389/fendo.2022.815703. View

Masuda M, Powell M, Chen S, Beer C, Fichna P, Rees Smith B . Autoantibodies to IA-2 in insulin-dependent diabetes mellitus. Measurements with a new immunoprecipitation assay. Clin Chim Acta. 1999; 291(1):53-66. DOI: 10.1016/s0009-8981(99)00199-0. View

Mahmud F, Elbarbary N, Frohlich-Reiterer E, Holl R, Kordonouri O, Knip M . ISPAD Clinical Practice Consensus Guidelines 2018: Other complications and associated conditions in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2018; 19 Suppl 27:275-286. PMC: 6748835. DOI: 10.1111/pedi.12740. View

Amoroso M, Achenbach P, Powell M, Coles R, Chlebowska M, Carr L . 3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD, to IA-2 and to ZnT8. Clin Chim Acta. 2016; 462:60-64. DOI: 10.1016/j.cca.2016.08.013. View

Torn C, Vaziri-Sani F, Ramelius A, Elding Larsson H, Ivarsson S, Amoroso M . Evaluation of the RSR 3 screen ICA™ and 2 screen ICA™ as screening assays for type 1 diabetes in Sweden. Acta Diabetol. 2022; 59(6):773-781. PMC: 9085662. DOI: 10.1007/s00592-022-01856-5. View

10.

Ziegler A, Rewers M, Simell O, Simell T, Lempainen J, Steck A . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013; 309(23):2473-9. PMC: 4878912. DOI: 10.1001/jama.2013.6285. View

11.

Eisenbarth G . Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986; 314(21):1360-8. DOI: 10.1056/NEJM198605223142106. View

12.

Primavera M, Giannini C, Chiarelli F . Prediction and Prevention of Type 1 Diabetes. Front Endocrinol (Lausanne). 2020; 11:248. PMC: 7326081. DOI: 10.3389/fendo.2020.00248. View

13.

Chen S, Willis J, Maclean C, Ananieva-Jordanova R, Amoroso M, Brooking H . Sensitive non-isotopic assays for autoantibodies to IA-2 and to a combination of both IA-2 and GAD65. Clin Chim Acta. 2005; 357(1):74-83. DOI: 10.1016/j.cccn.2005.02.006. View

14.

Lampasona V, Liberati D . Islet Autoantibodies. Curr Diab Rep. 2016; 16(6):53. DOI: 10.1007/s11892-016-0738-2. View

15.

Knip M, Korhonen S, Kulmala P, Veijola R, Reunanen A, Raitakari O . Prediction of type 1 diabetes in the general population. Diabetes Care. 2010; 33(6):1206-12. PMC: 2875424. DOI: 10.2337/dc09-1040. View

16.

Brooking H, Ananieva-Jordanova R, Arnold C, Amoroso M, Powell M, Betterle C . A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta. 2003; 331(1-2):55-9. DOI: 10.1016/s0009-8981(03)00088-3. View

17.

Prentice L, Phillips D, Sarsero D, Beever K, McLachlan S, Smith B . Geographical distribution of subclinical autoimmune thyroid disease in Britain: a study using highly sensitive direct assays for autoantibodies to thyroglobulin and thyroid peroxidase. Acta Endocrinol (Copenh). 1990; 123(5):493-8. DOI: 10.1530/acta.0.1230493. View

18.

Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, Laporte R, Tuomilehto J . Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care. 2000; 23(10):1516-26. DOI: 10.2337/diacare.23.10.1516. View

19.

Beever K, Bradbury J, Phillips D, McLachlan S, Pegg C, Goral A . Highly sensitive assays of autoantibodies to thyroglobulin and to thyroid peroxidase. Clin Chem. 1989; 35(9):1949-54. View

20.

Parikka V, Nanto-Salonen K, Saarinen M, Simell T, Ilonen J, Hyoty H . Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia. 2012; 55(7):1926-36. DOI: 10.1007/s00125-012-2523-3. View